Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $53.8 million.

  • Centessa Pharmaceuticals' Operating Expenses rose 1591.42% to $53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.8 million, marking a year-over-year increase of 3578.15%. This contributed to the annual value of $201.1 million for FY2024, which is 1286.6% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Operating Expenses stood at $53.8 million for Q3 2025, which was up 1591.42% from $54.7 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Operating Expenses peaked at $74.6 million during Q4 2024, and registered a low of $36.1 million during Q1 2024.
  • Its 4-year average for Operating Expenses is $49.6 million, with a median of $47.0 million in 2023.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 3127.28% in 2023, then skyrocketed by 7744.05% in 2024.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' Operating Expenses stood at $41.6 million in 2022, then rose by 1.03% to $42.0 million in 2023, then skyrocketed by 77.44% to $74.6 million in 2024, then fell by 27.88% to $53.8 million in 2025.
  • Its last three reported values are $53.8 million in Q3 2025, $54.7 million for Q2 2025, and $45.8 million during Q1 2025.